Steven Leonard Chapman Sells 2,552 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,552 shares of Natera stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total value of $233,201.76. Following the sale, the chief executive officer now owns 230,319 shares in the company, valued at $21,046,550.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The stock was sold at an average price of $93.13, for a total transaction of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The shares were sold at an average price of $65.09, for a total value of $964,178.17.

Natera Trading Up 0.5 %

Natera stock opened at $91.50 on Thursday. The stock has a market cap of $11.05 billion, a P/E ratio of -24.29 and a beta of 1.37. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The firm’s fifty day moving average price is $86.85 and its 200-day moving average price is $66.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Equities research analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Canaccord Genuity Group upped their price target on Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Piper Sandler upped their price objective on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. BTIG Research lifted their target price on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research report on Friday, April 5th. Finally, StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. RiverPark Advisors LLC bought a new position in shares of Natera in the 4th quarter worth $27,000. Principal Securities Inc. bought a new position in Natera in the fourth quarter valued at $32,000. Arcadia Investment Management Corp MI raised its position in Natera by 47.8% during the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 174 shares in the last quarter. Oliver Lagore Vanvalin Investment Group lifted its stake in Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Natera in the 3rd quarter worth about $44,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.